Amyndas Pharmaceuticals

#Amyndas is a pharmaceutical company developing #complement #therapeutics (#compstatins etc) for inflammatory diseases and disorders.

[Amyndas Pharmaceuticals @Amyndas]

Excited to announce that @Amyndas is a partner of the #HorizonEurope-funded project @fibrotarget which aims to advance our understanding of #IBD #fibrosis & #fibrostenosis and explore new targets for disease diagnosis and therapy

[FIBROTARGET @fibrotarget]

🎉We're proud to announce that @fibrotarget is now in action🎉

This #HorizonEurope project aims to advance inflammatory bowel disease (#IBD) diagnosis and therapies🔬

You can learn more about the 5-year initiative below in our LIVE website🌐
https://t.co/yG6hNdHfXo

#fibrosis

[Amyndas Pharmaceuticals @Amyndas]

We are thrilled to announce positive Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis. Our study met both its primary and secondary endpoints with prominent resolution of periodontal inflammation. https://t.co/aUlHrryQZI

[Dimitris Mastellos @dmastellos]

Massive congrats to @LambrisJD for making it to the #HighlyCited2020 researchers list of @webofscience for the third time in a row! A true pioneer in #complementbiology & #therapeutics, a #science mover and a #dogma shaker! Here's to many more! 👏👏https://t.co/96SQ513cpD

[Amyndas Pharmaceuticals @Amyndas]

To #AMY101 θα δοκιμαστεί σε COVID-19 ασθενείς σε 6 νοσοκομεία της Ελλάδος https://t.co/RrtDZgYPb3

[John D. Lambris, Ph.D. @LambrisJD]

Delighted to report that our study comparing C3 & C5 inhibition in severe #COVID19 is now out! Promising results for #AMY101 Great team effort by @PennMedicine @SanRaffaeleMI @NCSR_Demokritos @infrathrace @Columbia @uni_ulm @UninaIT @usponline @Amyndas https://t.co/oWcN9yhESm

[Amyndas Pharmaceuticals @Amyndas]

Check out our new EXCITING data on the efficacy of AMY-101 in #COVID19 patients supporting the GREAT potential of #complement #C3 inhibition for a broad therapeutic effect. #AMY101 #thromboinflammation

[John D. Lambris, Ph.D. @LambrisJD]

Check out our new study comparing C3 inhibition with C5 blockade in #COVID19: our early clinical findings offer important insight into the differential mechanistic basis of C3 & C5 inhibition and support a broader therapeutic profile of #AMY101 in COVID-19 #thromboinflammation

[Amyndas Pharmaceuticals @Amyndas]

Great achievement for our technology!

[John D. Lambris, Ph.D. @LambrisJD]

Complement fuels #COVID19 immunothrombosis and #C3 inhibition intercepts the #platelet #neutrophil NET-thrombin axis attenuating #NET-driven TF-induced thrombogenicity #AMY101 @Amyndas #therapy @PennMedicine @Aristoteleio @uoaofficial @NCSR_Demokritos #UniversityofThrace

[Amyndas Pharmaceuticals @Amyndas]

Ευχαριστούμε τη Θεοδώρα Τσώλη και το @tovimagr για την συνέντευξη και εμπεριστατωμένη παρουσίαση του κλινικού προγράμματος αξιολόγησης της θεραπευτικής δράσης του αναστολέα C3 #ΑΜΥ101 σε ασθενείς #COVID19 https://t.co/W25vHQYzAx

[Dimitris Mastellos @dmastellos]

Complement C3 as a Target of Host Modulation in #Periodontitis: Following validation in NHP models of periodontal #inflammation, C3 inhibition moves to the bedside #complementbiology #oralcavity #dysbiosis #therapeutics #compstatins #AMY101 https://t.co/jeMqRuaEeW

[John D. Lambris, Ph.D. @LambrisJD]

Κορωνοϊός -Εγκριση από τον Αμερικανικό Οργανισμό Φαρμάκων στην ελληνική «Αμύντας» για κλινική δοκιμή σε ασθενείς https://t.co/pgY4w3Asww

[Amyndas Pharmaceuticals @Amyndas]

We are thrilled to announce that the most advanced complement C3 inhibitor #AMY101 has received FDA approval for a randomized Phase 2 trial in #COVID19 patients with ARDS. AMY-101 suppresses cytokine release and thromboinflammation in COVID-19. https://t.co/4vj6YHkRIP

[Amyndas Pharmaceuticals @Amyndas]

Κορωνοϊός: Ενθαρρυντικά τα αποτελέσματα φαρμάκου από την εταιρεία «Αμύντας» https://t.co/m5EJRLsyRB

[Amyndas Pharmaceuticals @Amyndas]

Κορωνοϊός: Ενθαρρυντικά τα αποτελέσματα φαρμάκου από την εταιρεία «Αμύντας» https://t.co/m5EJRLsyRB

[Amyndas Pharmaceuticals @Amyndas]

Excited to announce the first case of #COVID19 successfully treated with our #complement C3 therapeutic #AMY101 . Encouraging results open the window for therapeutic C3 inhibition by AMY101 in COVID19 https://t.co/EtiASi78L4

[Amyndas Pharmaceuticals @Amyndas]

Prospects have never been better for testing novel C3-targeted therapeutics in ocular indications #AMD Check out this new paper by our founder @LambrisLab reporting on the promising ocular PK profile of a fourth-generation #compstatin analog clinically developed by @Amyndas

[John D. Lambris, Ph.D. @LambrisJD]

Happy to share our recent paper on the promising #ocular PK and tissue distribution profile of a fourth-generation #compstatin-based #C3 inhibitor This work could lead to more effective ocular #therapeutics for diseases fueled by C3 dysregulation @Penn @Amyndas

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Therapeutic targeting of the complement system - a new poster published today https://t.co/u5S0swWI9Z And for more, here's a recent review https://t.co/cxAOZGtTey

[Amyndas Pharmaceuticals @Amyndas]

We’re thrilled that our Founder @Penn Prof John Lambris is on the #WebofScience #HighlyCitedResearchers 2019 list for the 2nd consecutive year! We’re grateful for his contributions in helping us develop the most advanced #ComplementTherapeutics #amyndas @ComplementSoc @LambrisLab

[Dimitris Mastellos @dmastellos]

Congratulations to @Penn Prof John Lambris @LambrisLab for being recognized as a #WebofScience Highly Cited Researcher for a second consecutive year! We are all so very proud of you! #HighlyCited2019 @PennMedNews @webofscience @clarivate @ComplementSoc @AegeanConf

[Dimitris Mastellos @dmastellos]

Academic research & industrial innovation are inherently connected. However, #stealth corporate research conducted outside the #peer_review system creates impediments to therapeutic #drug development. Read our comment now published in @NatImmunol Thread 1/ https://t.co/64QyL4JM8M

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Our September issue is out! Read about targeting immunometabolism, complement therapeutics, oncolytic virotherapy, harnessing machine learning for cellular imaging and more https://t.co/dHxeSuKdbB